Basilea's antibiotic Zevtera receives Swiss approval
This article was originally published in Scrip
BasileaPharmaceutica has obtained regulatory approval in Switzerland for Zevtera (ceftobiprole medocaril for injection), a broad-spectrum anti-MRSA cephalosporin antibiotic, for the treatment of complicated skin and soft tissue infections including diabetic foot infections.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.